Skip to main content

Table 5 Relative healthcare cost per month by baseline SHPT parameters, Hungary, Italy, Portugal, Spain, and Turkey

From: Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study

Baseline level* n Relative cost coefficient (95% CI)
Univariate analysis Multivariate analysis
iPTH, pg/mL    
  < 75 1054 1.01 (0.92, 1.12) 0.98 (0.89, 1.09)
  ≥ 75 – < 150 1145 0.98 (0.89, 1.08) 1.00 (0.91, 1.10)
  ≥ 150 – ≤ 300 (reference) 1394 1.00 1.00
  > 300 – ≤ 600 1140 1.11 (1.01, 1.22) 1.11 (1.01, 1.22)
  > 600 653 1.53 (1.36, 1.71) 1.41 (1.25, 1.59)
Total calcium (mmol/L)    
  < 2.10 mmol/L 833 1.06 (0.97, 1.17) 1.01 (0.92, 1.11)
  ≥ 2.10 – ≤ 2.37 mmol/L (reference) 2980 1.00 1.00
  > 2.37 mmol/L 1405 1.14 (1.06, 1.24) 1.08 (1.00, 1.17)
  Missing 168 1.26 (1.03, 1.54) 1.54 (1.18, 2.00)
Phosphate (mmol/L)    
  < 1.13 mmol/L 827 0.75 (0.68, 0.82) 0.75 (0.68, 0.82)
  ≥ 1.13 – ≤ 1.78 mmol/L (reference) 3104 1.00 1.00
  > 1.78 mmol/L 1208 1.39 (1.28, 1.51) 1.38 (1.27, 1.50)
  Missing 247 0.94 (0.79, 1.12) 0.70 (0.55, 0.88)
  1. iPTH, intact parathyroid hormone.
  2. *Mean during 3-month baseline period.
  3. Adjusted for duration of follow-up.
  4. Adjusted for iPTH, total calcium, phosphate, duration of follow-up, age, sex, chronic kidney disease aetiology, history of cardiovascular disease, diabetes and cancer, dialysis vintage, C-reactive protein, albumin, haemoglobin, ferritin, total cholesterol and blood leukocyte count.